International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.
New liver disease medications backed by FDA approval now have expert guidance on selecting patients and monitoring safety in real-world practice.
This international expert review is the first consensus guidance on resmetirom and semaglutide for MASH, the first pharmacological therapies to receive FDA approval for this liver disease affecting over 6 million Americans. The panel addresses patient selection, treatment sequencing, monitoring strategies, and open questions, providing practitioners with a practical framework for these landmark therapies.
What the study was
- Study design
- International expert panel review/consensus
- Population
- MASH (metabolic-associated steatohepatitis) patients
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Gut
Why it surfaced
First expert guidance on two newly FDA-approved MASH therapies covering 6M+ affected US patients; immediately practice-informing for hepatology and primary care.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.